The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

S. Pignata, G. Scambia, D. Lorusso, U. De Giorgi, M. O. Nicoletto, R. Lauria, A. M. Mosconi, C. Sacco, C. Omarini, P. Tagliaferri, G. Ferrandina, S. Cinieri, A. Savarese, G. Valabrega, C. Pisano, V. Salutari, F. Raspagliesi, B. Kopf, S. C. Cecere, G. AmadioG. Maltese, M. Di Napoli, S. Greggi, S. Signoriello, G. Daniele, A. Sacco, S. Losito, N. Normanno, F. Perrone, C. Gallo, M. C. Piccirillo, MITO Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS
Original languageItalian
Pages (from-to)535-540
Number of pages6
JournalGynecologic Oncology
Volume153
Issue number3
DOIs
Publication statusPublished - 2019

Cite this